[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tinnitus-noise-induced\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tinnitus-noise-induced":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100576208","tinnitus-patient-preferences-survey-100576208",false,"NCT06782308","Tinnitus Patient Preferences Survey","Inclusion criteria:\n\n* Individuals aged 18 or older suffering from subjective tinnitus\n* Self-reported or healthcare professional-diagnosed chronic (lasting 3 months or longer), subjective, burdensome tinnitus\n\nExclusion criteria:\n\n* Individuals under 18 years of age\n* Healthy volunteers without tinnitus","ALL","18 Years",{"count":18,"type":19},500,"ESTIMATED","1 Day","OBSERVATIONAL","The goal of this survey is to assess several aspects related to patient preferences regarding interventions for alleviating tinnitus through invasive electrical brain stimulation (neuromodulation). This survey covers the acceptance of a surgically-placed brain implant, of its associated risks related to the neurosurgical procedure, usability considerations, and the willingness\u002Fability to pay for such a treatment.\n\nNeurosoft Bioelectronics will use the collected patients' feedback and usability preferences data for the development of a novel minimally invasive brain implant aimed at alleviating tinnitus.",[24,25,26,27],"Tinnitus, Subjective","Tinnitus, Bilateral","Tinnitus, Noise Induced","Tinnitus, Hearing Loss, Cochlear Implant Users",[29,30,31,32,33,34,35,36,37,38,39,40,41],"tinnitus","iBCI","brain implant","survey","risks acceptance","user preferences","patient preferences","subjective tinnitus","chronic tinnitus","severe tinnitus","catastrophic tinnitus","invasive neuromodulation","surgical treatment","RECRUITING","2026-04-07",{"date":45,"type":46},"2026-04-08","ACTUAL",{"date":48,"type":46},"2025-01-13",{"date":50,"type":19},"2026-12-30",{"name":52,"class":53},"Nicolas Gninenko","INDUSTRY",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":15,"minAge":16,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":77,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":54},"100628951","multimodal-therapy-for-somatosensory-tinnitus-100628951","NCT07468318","Multimodal Therapy for Somatosensory Tinnitus","Multimodal Therapeutic Approach to Tinnitus Treatment With Focus on Somatosensory Components: A Randomised Controlled Trial Integrating Physiotherapy, Structured Exercise Program, and Psychological Intervention","SOMATIN","Inclusion Criteria:\n\n* Age 18-70 years (inclusive)\n* Chronic subjective tinnitus present for ≥6 months\n* Tinnitus Handicap Inventory (THI) score ≥18 points (indicating at least mild tinnitus handicap)\n* Positive somatosensory modulation test: ability to reproducibly modulate tinnitus (change in loudness, pitch, or quality) through at least one of the following manoeuvres:\n* Jaw movements (mouth opening, lateral excursion, protrusion, clenching)\n* Neck movements (flexion, extension, rotation, lateral flexion)\n* Pressure on specific head\u002Fneck muscles\n* Eye movements or shoulder elevation\n* Willing and able to attend all study sessions over 28 weeks\n* Adequate cognitive capacity to understand study procedures and complete questionnaires in the Czech language\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Audiological\u002FENT Exclusions:\n* Objective or pulsatile tinnitus\n* Active ear pathology requiring treatment:\n* Acute otitis media or externa\n* Chronic suppurative otitis media\n* Cholesteatoma\n* Meniere's disease with recent vertigo attacks (\\\u003C3 months)\n* Suspected retrocochlear pathology:\n* Acoustic neuroma (vestibular schwannoma)\n* Cerebellopontine angle tumor\n* Neurological Exclusions:\n* Neurological disease affecting brainstem or auditory pathways:\n* Multiple sclerosis with brainstem involvement\n* Stroke affecting auditory pathways\n* Brain tumor\n* Epilepsy or active seizure disorder\n* Musculoskeletal Exclusions:\n* Contraindications to manual therapy:\n* Severe cervical spine instability\n* Rheumatoid arthritis with atlantoaxial instability\n* Down syndrome\n* Vertebrobasilar insufficiency\n* Severe osteoporosis with fracture risk\n* Recent cervical spine surgery (\\\u003C6 months)\n* Recent head or neck trauma (\\\u003C3 months)\n* Ongoing physiotherapy or manual therapy for temporomandibular joint or cervical spine (\\\u003C3 months prior to enrollment)\n* Psychiatric Exclusions:\n* Severe psychiatric disorder:\n* Active psychosis\n* Severe depression requiring inpatient treatment\n* Acute suicidal ideation (PHQ-9 item 9 score ≥2)\n* Active substance abuse disorder\n* Other Exclusions:\n* Pregnancy (due to modifications needed in physical examination and treatment)\n* Ongoing litigation or compensation claims related to tinnitus or hearing loss\n* Current participation in another interventional clinical trial\n* Expected change of residence or long-term absence (\\>2 weeks) during the study period\n* Unable or unwilling to comply with study procedures and attend all sessions",true,"70 Years",{"count":66,"type":19},160,"INTERVENTIONAL",[69],"NA","Tinnitus (ringing or buzzing in the ears) affects approximately 10-15% of the adult population and significantly reduces quality of life in many patients. In a substantial proportion of cases, tinnitus is associated with dysfunction of the temporomandibular joint (TMJ) and cervical spine - this subtype is called somatosensory tinnitus.\n\nThis randomised controlled trial investigates the effectiveness of a multimodal intervention combining: (1) physiotherapy targeting TMJ and cervical spine dysfunction, (2) a structured combined exercise program (aerobic + resistance + breathing), and (3) psychological support (cognitive-behavioural psychoeducation) in patients with chronic somatosensory tinnitus.\n\nThe study also examines the acute effects of different types and intensities of physical exercise on tinnitus perception, and performs psychometric validation of Czech-language tinnitus assessment questionnaires.\n\nParticipants (N=160, aged 18-70 years) will be randomly assigned to either the multimodal intervention group (8 weeks, 5 sessions\u002Fweek) or a control group. Follow-up assessments will be conducted at 3, 12, and 24 months. The primary outcome is the change in the Tinnitus Handicap Inventory (THI) score.",[72,26,24,73,74,75,76],"Ear Noise","Headache Other","Temporomandibular Dysfunction","Cervical Migraine Syndrome","Chronic Tinnitus",[78,29,79,80,81,82],"exercise therapy","multimodal therapy","subjective noise","somatosensory tinnitus","physiotherapy","NOT_YET_RECRUITING","2026-03-11",{"date":86,"type":46},"2026-03-12",{"date":88,"type":19},"2027-01-01",{"date":90,"type":19},"2030-12-31",{"name":92,"class":93},"Charles University, Czech Republic","OTHER",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":67,"phases":103,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":121},"100367596","phase-2-tnf--treatment-of-blast-induced-tinnitus-100367596","NCT04066348","TNF-α Treatment of Blast-Induced Tinnitus","Clinical Trial of Etanercept (TNF-α Blocker) for Treatment of Blast-Induced Tinnitus","Inclusion Criteria:\n\n1. Tinnitus of at least a moderate severity as defined by a score of ≥ 25 points or higher on the Tinnitus Functional Index (TFI) questionnaire associated with one or more of the following:\n\n   1. Blast- or noise exposure\n   2. Traumatic brain injury (TBI) and\u002For concussion diagnosed by a health care provider.\n2. Able to provide written informed consent.\n3. Age: Minimum 18 years of age at the time of enrollment.\n4. Other concurrent treatments for tinnitus: A four-week washout from any other tinnitus treatment or management program is required prior to entering this study.\n\n   a) Hearing aids are permitted if the participant has been wearing them for at least 4 weeks.\n5. Hearing function: All degrees of hearing function can be included, recognizing that individuals with profound, bilateral hearing loss will not be able to perform tinnitus evaluations and hearing tests but will be able to rate subjective tinnitus loudness, annoyance and impact on life. This is an important sub-population because of the challenges in treating them with acoustic therapy and the need for a medical intervention.\n6. Additional tinnitus characteristics:\n\n   a) Tinnitus history: Onset associated with blast and\u002For noise exposure or associated with diagnosed TBI and\u002For concussion. Subjects will have blast exposure, noise exposure, traumatic brain injury (TBI), and\u002For concussion impact, defined as exposure\u002Fimpact less than or longer than six months at time of enrollment.\n\n   i. Participants enrolled with tinnitus associated with TBI and\u002For concussion must have received a diagnosis of TBI and\u002For concussion by a health care provider.\n\n   b) Stability: Constant (not pulsatile or intermittent). c) Location of tinnitus perception: Unrestricted. Tinnitus may be unilateral, bilateral, or perceived in the head.\n\nExclusion Criteria:\n\n1. History or evidence of any of the following: Significant brain malformation; cerebral vascular events (such as strokes); neurodegenerative disorders affecting the brain, such as Parkinson's disease, ALS, or Huntington's disease; multiple sclerosis, Guillain-Barré syndrome, or any other disease involving demyelination disorder or any finding suggesting a demyelination disease or disorder; prior brain surgery.\n\n   a. The following surgical procedures are not exclusionary: Evacuation of subdural hematoma, insertion of intracranial pressure monitor device, craniectomy\n2. Active malignant neoplasm such as lymphoma or solid tumors or history of malignant neoplasm, excluding successfully treated squamous cell carcinoma or basal carcinoma of the skin or cervical cancer.\n3. Diagnosis of congestive heart failure.\n4. History of diagnosed seizure disorder or epilepsy.\n5. Diagnosis of myelodysplastic syndrome or aplastic anemia, white blood cell count \\\u003C 4000, or platelet count \\\u003C 150,000.\n6. Subjects who currently have an active infection, including tuberculosis, HIV, hepatitis B, and\u002For chicken pox.\n\n   a. Patients with latent hepatitis B infection are also excluded from participation.\n7. Scheduled to receive a live vaccine during study participation or received a live vaccine within 2 weeks prior to screening visit\u002Fprocedures.\n8. Diagnosis of an auto-immune disease that, in the opinion of the investigator, would cause a weakened immune system.\n\n   a) Autoimmune thyroid disease is not considered an exclusionary autoimmune disease for participation in this study.\n9. Diabetes.\n10. Ongoing treatment with or plans to begin taking any of the following contraindicated medications: Cyclophosphamide or sulfasalazine; abatacept, anakinra, or any other immunomodulatory biologic therapy; sulfonylureas, meglitinides, or insulin.\n11. Subjects who cannot communicate reliably with research team members or who are not likely to be able to complete the requirements of the trial per the discretion of the investigator.\n12. Subjects who have participated in a drug clinical trial within the last 30 days before the start of this one.\n13. Pregnancy or planned pregnancy during the study.\n14. Women who are lactating or are of child-bearing-age without use of contraception.\n15. MMSE score \\\u003C 24.\n16. Clinically significant out of range laboratory values for protocol required laboratory tests as assessed by the investigator.",{"count":102,"type":19},88,[104],"PHASE2","The purpose of this multi-site research study is to determine if Etanercept, compared to a placebo, significantly reduces the severity of tinnitus (ringing in the ears) associated with history of blast and\u002For noise exposure or associated with Traumatic Brain Injury (TBI) and\u002For concussion. Individuals who qualify will be randomized into one of two groups: The group receiving the medication Etanercept or the group receiving a saline solution placebo.",[26],[29,108,109,110,111],"etanercept","tinnitus function index","tinnitus primary function","audiological evaluation","2026-02-19",{"date":114,"type":46},"2026-02-23",{"date":116,"type":46},"2022-07-01",{"date":118,"type":19},"2026-09",{"name":120,"class":93},"Wayne State University",4]